Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 1411 AL 1425

RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein

Srivastava A, Alam P, Caughey B.

Biomolecules. 2022 Apr 14;12(4):576. doi: 10.3390/biom12040576.

Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases

Pottoo FH, Ibrahim AM, Alammar A, Alsinan R, Aleid M, Alshehhi A, Alshehri M, Mishra S, Alhajri N.

Pharmaceuticals (Basel). 2022 Mar 27;15(4):408. doi: 10.3390/ph15040408.

GBA Variants and Parkinson Disease: Mechanisms and Treatments

Smith L, Schapira AHV.

Cells. 2022 Apr 8;11(8):1261. doi: 10.3390/cells11081261.

Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery

Esfandiary A, Finkelstein DI, Voelcker NH, Rudd D.

Cells. 2022 Apr 15;11(8):1353. doi: 10.3390/cells11081353.

Ubiquitin Proteasome System and Microtubules Are Master Regulators of Central and Peripheral Nervous System Axon Degeneration

Cartelli D, Cavaletti G, Lauria G, Meregalli C.

Cells. 2022 Apr 15;11(8):1358. doi: 10.3390/cells11081358.

Drug Nanocrystals: Focus on Brain Delivery from Therapeutic to Diagnostic Applications

Zingale E, Bonaccorso A, Carbone C, Musumeci T, Pignatello R.

Pharmaceutics. 2022 Mar 23;14(4):691. doi: 10.3390/pharmaceutics14040691.

Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date

Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, Malungelo Khamanga SM, Makoni PA.

Pharmaceutics. 2022 Apr 11;14(4):836. doi: 10.3390/pharmaceutics14040836.

CD40-CD40L in Neurological Disease

Ots HD, Tracz JA, Vinokuroff KE, Musto AE.

Int J Mol Sci. 2022 Apr 8;23(8):4115. doi: 10.3390/ijms23084115.

Circular RNAs: Emblematic Players of Neurogenesis and Neurodegeneration

D'Anca M, Buccellato FR, Fenoglio C, Galimberti D.

Int J Mol Sci. 2022 Apr 8;23(8):4134. doi: 10.3390/ijms23084134.

Biomarker of Neuroinflammation in Parkinson's Disease

Liu TW, Chen CM, Chang KH.

Int J Mol Sci. 2022 Apr 8;23(8):4148. doi: 10.3390/ijms23084148.

Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase

Nagatsu T, Nakashima A, Watanabe H, Ito S, Wakamatsu K.

Int J Mol Sci. 2022 Apr 10;23(8):4176. doi: 10.3390/ijms23084176.

Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy

Ortega Á, Salazar J, Galban N, Rojas M, Ariza D, Chávez-Castillo M, Nava M, Riaño-Garzón ME, Díaz-Camargo EA, Medina-Ortiz O, Bermúdez V.

Int J Mol Sci. 2022 Apr 11;23(8):4196. doi: 10.3390/ijms23084196.

Tools and Biomarkers for the Study of Retinal Ganglion Cell Degeneration

Corral-Domenge C, de la Villa P, Mansilla A, Germain F.

Int J Mol Sci. 2022 Apr 13;23(8):4287. doi: 10.3390/ijms23084287.

Mouse Mutants of Gpr37 and Gpr37l1 Receptor Genes: Disease Modeling Applications

Massimi M, Di Pietro C, La Sala G, Matteoni R.

Int J Mol Sci. 2022 Apr 13;23(8):4288. doi: 10.3390/ijms23084288.

Revisiting the Role of Astrocytic MAOB in Parkinson's Disease

Nam MH, Sa M, Ju YH, Park MG, Lee CJ.

Int J Mol Sci. 2022 Apr 18;23(8):4453. doi: 10.3390/ijms23084453.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias